A Phase 2/3 interventional study of Transcutaneous electrical stimulation and Sham electrical stimulation in Disorders of Consciousness Due to Severe Brain Injury, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Xijing Hospital · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Consciousness Disorders with a site in China — 30 open to participants now, 31 under way, 1 of them phase 3. Consciousness Disorders · China.
Among the 70 studies in Consciousness Disorders with a site in China, this one is the 6th largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 29 of the 30 other live ones, and was the 68th registered.
291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.
Browse Consciousness Disorders studies →30 of the 70 studies in Consciousness Disorders with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Zhujiang Hospital · Sites in China
Ages 18–70
Guangzhou General Hospital of Guangzhou Military Command · Sites in China
Ages 3–65
Xijing Hospital · Sites in China
Ages 18–65
Huashan Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 2
First in 2008; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 47 across 192 interventional studies indexed under Consciousness Disorders.
Median enrollment 60 across the 40 interventional studies, 120 across the 30 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 70 have an industry lead sponsor. The 10 most frequent:
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Xijing Hospital has 8 studies filed under Consciousness Disorders — fewer than ten, so there is no comparison to draw.
8 of the studies in Consciousness Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06406413First Affiliated Hospital of Zhejiang UniversityMicro-movements in Patients With Prolonged Disorders of Consciousness | 2026-12 |
| NCT06088628First Affiliated Hospital of Zhejiang UniversityMicro-expressions in Patients With Prolonged Disorders of Consciousness | 2026-12 |
| NCT06268236The Second Affiliated Hospital, Guangzhou University of Traditional Chinese MedicineElectro-acupuncture to Treat Disorder of Consciousness | 2026-12-31 |
| NCT07183670Hongying Jiang, MDA Speaking-Valve-Based Decannulation Protoco for Patients With a Prolonged Disorders of Consciousness | 2027-02-01 |
| NCT07173634Hongying Jiang, MDSpeaking Valve Trial vs. Capping Trial for Tracheostomy Decannulation in Prolonged Disorders of Consciousness | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 70 studies in Consciousness Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Effective treatment options for disorders of consciousness (DoC) remain limited, and available interventions show heterogeneous efficacy. To date, limited evidences support the use of amantadine and transcranial direct current stimulation in this population.
Bloodletting puncture (BP) at the hand twelve Jing-Well points (HTWPs) has been traditionally used in China as an empirical therapy for DoC; however, its efficacy has not been established by robust clinical evidence. Transcutaneous electrical acupoint stimulation (TEAS) provides a modern, noninvasive alternative for acupoint stimulation. The Wells-DoC trial, a multicenter, randomized, controlled, open-label study with blinded endpoint assessment, provided preliminary evidence that TEAS applied at the hand twelve Jing-Well points was associated with a numerically higher proportion of consciousness improvement in patients with DoC, although the difference did not reach statistical significance. These findings support the need for further evaluation in an adequately powered randomized controlled trial.
The Wells-DoC II trial is a multicenter, randomized, controlled, double-blind clinical trial designed to evaluate the efficacy and safety of TEAS at the twelve Jing-Well points of the hand in patients with DoC. The primary objective of the Wells-DoC II trial is to determine whether TEAS applied at the twelve Jing-Well points of the hand improves consciousness in adults with DoC. The primary endpoint is the proportion of patients achieving consciousness improvement after 14 consecutive days of treatment, compared between the TEAS group and the sham stimulation (placebo control) group.
The secondary objectives are to assess the effects of TEAS versus sham stimulation on: (1) changes in Coma Recovery Scale-Revised (CRS-R) scores at 7 and 14 days; (2) change in ABCD model classification at day 14; and (3) functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 3 and 6 months after enrollment.
A total of 160 patients will be recruited over a 28-month period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the treatment group will receive transcutaneous electrical acupoint stimulation at hand twelve jing-well points for 14 consecutive days, twice a day, combined with conventional treatment or rehabilitation for patients with DoC.
Device: Transcutaneous electrical stimulation
Patients randomized to the Sham electrical stimulation group will receive sham electrical acupoint stimulation at hand twelve jing-well points for 14 consecutive days, twice a day, combined with conventional treatment or rehabilitation for patients with DoC.
Device: Sham electrical stimulation
Transcutaneous electrical acupoint stimulation at hand twelve jing-well points
Sham electrical acupoint stimulation at hand twelve jing-well points
Proportion of consciousness improvement after 14 consecutive days of treatment
The primary effectiveness outcome was the proportion of patients with consciousness improvement after 14 consecutive days of treatment, wherein improvements from unresponsive wakefulness syndrome (UWS)/vegetative state (VS) to minimally conscious state (MCS) or emergence from minimally conscious state (EMCS), from MCS minus (MCS-) to MCS plus (MCS+) or EMCS, or from MCS+ to EMCS signify a consciousness improvement. Diagnoses of UWS/VS, MCS (minus or plus) and EMCS were determined based on the presence of specific Coma Recovery Scale-Revised (CRS-R) subscale items, assessed by a trained neurologist. The hierarchical order of consciousness levels from worst to best is UWS/VS, MCS-, MCS+, and EMCS.
Time frame: 14 days after treatment
Changes in Coma Recovery Scale-Revised (CRS-R) scores after 7 days of treatment
CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome.
Time frame: 7 days after treatment
Changes in sub scale of Coma Recovery Scale-Revised (CRS-R) scores after 7 days of treatment
CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome. Each sub scale consists of multiple hierarchically organized questions, with higher scores indicating greater performance.
Time frame: 7 days after treatment
Changes in Coma Recovery Scale-Revised (CRS-R) scores after 14 days of treatment
CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome.
Time frame: 14 days after treatment
Changes in sub scale of Coma Recovery Scale-Revised (CRS-R) scores after 14 days of treatment
CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome. Each sub scale consists of multiple hierarchically organized questions, with higher scores indicating greater performance.
Time frame: 14 days after treatment
Changes in ABCD model classification after 14 days of treatment
This model classifies the power spectrum of resting-state EEG data into four categories: A, B, C, and D. Type A exhibit a power spectrum peak in the delta range (0-4 Hz), indicative of a completely disconnected thalamocortical network. Type B shows a primary power spectrum peak in the theta range (4-8 Hz), reflecting a severely disconnected thalamocortical network. Type C exhibits power spectrum peaks in both the theta (4-8 Hz) and beta (13-24 Hz) ranges, indicative of a moderately disconnected thalamocortical network. Type D shows power spectrum peaks in the alpha (8-13 Hz) and beta ranges, representing a fully intact thalamocortical network.
Time frame: 14 days after treatment
Functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 3 months after enrollment
Functional outcomes were assessed at 3 months after enrollment using the Glasgow Outcome Scale-Extended (GOSE; range 1-8, where higher scores indicate better functional outcomes).
Time frame: 3 months after enrollment
Functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 6 months after enrollment
Functional outcomes were assessed at 6 months after enrollment using the Glasgow Outcome Scale-Extended (GOSE; range 1-8, where higher scores indicate better functional outcomes).
Time frame: 6 months after enrollment
Incidence of adverse events during 6 months after enrollment
The safety outcome was the incidence of adverse events during 6 months after enrollment.
Time frame: 6 months after enrollment
Incidence of severe adverse events during 6 months after enrollment
The safety outcome was the incidence of severe adverse events during 6 months after enrollment.
Time frame: 6 months after enrollment
Incidence of adverse events prespecified for transcutaneous electrical stimulation during treatment
The following adverse events are prespecified for transcutaneous electrical stimulation applied to the twelve Jing-Well points of the hand, including treatment intolerance: manifested as observable distress responses during stimulation, (e.g., painful facial expressions, moaning, crying, or involuntary head movements); local adverse effects: skin infection (e.g., redness, swelling, suppuration), subcutaneous ecchymosis, and skin burns (e.g., blistering or eschar formation) at stimulation sites; and systemic adverse effects: epileptic seizures temporally associated with the intervention.
Time frame: from the first treatment on Day 1 to the completion of the last treatment on Day 14
Incidence of severe adverse events prespecified for transcutaneous electrical stimulation during treatment
The following adverse events are prespecified for transcutaneous electrical stimulation applied to the twelve Jing-Well points of the hand, including treatment intolerance: manifested as observable distress responses during stimulation, (e.g., painful facial expressions, moaning, crying, or involuntary head movements); local adverse effects: skin infection (e.g., redness, swelling, suppuration), subcutaneous ecchymosis, and skin burns (e.g., blistering or eschar formation) at stimulation sites; and systemic adverse effects: epileptic seizures temporally associated with the intervention. Serious adverse events (SAEs) are defined as any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity
Time frame: from the first treatment on Day 1 to the completion of the last treatment on Day 14
Plan to share: Undecided — NOT YET DECIDED
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.